Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Oct 17, 2024

BUY
$2.2 - $4.98 $497,516 - $1.13 Million
226,144 Added 128.98%
401,481 $915,000
Q2 2024

Aug 14, 2024

BUY
$2.2 - $4.98 $497,516 - $1.13 Million
226,144 Added 128.98%
401,481 $915,000
Q1 2024

Oct 17, 2024

SELL
$2.1 - $4.83 $474,902 - $1.09 Million
-226,144 Reduced 56.33%
175,337 $757,000
Q1 2024

Aug 16, 2024

BUY
$2.1 - $4.83 $11,085 - $25,497
5,279 Added 3.1%
175,337 $757,000
Q1 2024

May 15, 2024

BUY
$2.1 - $4.83 $11,085 - $25,497
5,279 Added 3.1%
175,337 $757,000
Q4 2023

Aug 16, 2024

SELL
$1.12 - $3.73 $259,193 - $863,207
-231,423 Reduced 57.64%
170,058 $518,000
Q4 2023

Feb 13, 2024

BUY
$1.12 - $3.73 $151,104 - $503,232
134,915 Added 383.9%
170,058 $518,000
Q3 2023

Nov 15, 2023

SELL
$1.22 - $2.67 $136,953 - $299,726
-112,257 Reduced 76.16%
35,143 $50,000
Q2 2023

Aug 14, 2023

SELL
$2.46 - $3.14 $284,530 - $363,181
-115,663 Reduced 43.97%
147,400 $367,000
Q1 2023

May 15, 2023

SELL
$2.57 - $8.16 $276,557 - $878,097
-107,610 Reduced 29.03%
263,063 $705,000
Q4 2022

Feb 14, 2023

BUY
$5.19 - $13.5 $168,047 - $437,116
32,379 Added 9.57%
370,673 $2.01 Million
Q3 2022

Nov 14, 2022

BUY
$5.17 - $16.99 $804,674 - $2.64 Million
155,643 Added 85.21%
338,294 $4.23 Million
Q2 2022

Oct 27, 2022

SELL
$4.04 - $8.51 $372,920 - $785,532
-92,307 Reduced 33.57%
182,651 $903,000
Q2 2022

Aug 15, 2022

SELL
$4.04 - $8.51 $372,920 - $785,532
-92,307 Reduced 33.57%
182,651 $903,000
Q1 2022

Oct 27, 2022

BUY
$7.6 - $11.02 $701,533 - $1.02 Million
92,307 Added 50.54%
274,958 $2.09 Million
Q1 2022

May 13, 2022

SELL
$7.6 - $11.02 $660,136 - $957,197
-86,860 Reduced 24.01%
274,958 $2.09 Million
Q4 2021

Feb 14, 2022

BUY
$10.16 - $16.17 $156,504 - $249,082
15,404 Added 4.45%
361,818 $3.69 Million
Q3 2021

Nov 15, 2021

BUY
$13.16 - $22.47 $4.56 Million - $7.78 Million
346,414 New
346,414 $4.65 Million

Others Institutions Holding GTHX

About G1 Therapeutics, Inc.


  • Ticker GTHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,746,800
  • Market Cap $306M
  • Description
  • G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...
More about GTHX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.